Loading stock data…
DNLI
$20.79+1.25 (+6.40%)
After Hours$20.79+0.00 (+0.00%)· Last close Jun 9
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Denali Therapeutics Inc. in the Healthcare sector is trading at $20.79 with a market capitalization of $3.1B. Wall Street consensus targets $33.93 (15 analysts), implying a +63.2% move over the next 12 months. The stock is currently 13% below its 52-week high of $23.77, remaining 14.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +63.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$20.79
Potential Downside
0%
Whystock Fair Value$20.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$33.93+63.2%
Range$20.00 – $42.00
Fundamentals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflamma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.86%
Volume
Today's trading volume
1.86M
Recent News
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline
Biogen and Denali Therapeutics have discontinued development of BIIB122 for early-stage Parkinson's disease. The decision follows Phase 2b LUMA trial results, where BIIB122 did not meet efficacy endpoints. The outcome affects Biogen's efforts in neurodegenerative diseases and LRRK2 inhibitor research. For investors tracking NasdaqGS:BIIB, the update comes with the stock trading at $192.23. The shares are up 46.6% over the past year but down 36.4% over three years and down 51.4% over five...
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos
We just covered the Jeff Bezos Stock Portfolio: Top 10 Stock Picks and Denali Therapeutics Inc. (NASDAQ:DNLI) ranks 10th on this list. Jeff Bezos established a strategic relationship with Denali Therapeutics Inc. (NASDAQ:DNLI) through his personal venture capital entity, Bezos Expeditions, identifying the biotech firm as a premier player in neurodegenerative disease research. Bezos backed […]
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says
Denali Therapeutics' (DNLI) investors will now look at its other pipeline assets and broader platfor
Stocks Settle Higher on Iran Peace Hopes and Tech Strength
The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. June E-mini S&P futures (ESM26 ) rose +0.35%, and June E-mini Nasdaq futures...
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks
Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA study failed to meet its endpoints. Legal investigations have been launched into Biogen following missed endpoints in the Phase 2 CELIA study for Alzheimer's therapy diranersen. These developments affect Biogen's pipeline in neurodegenerative diseases and add legal and regulatory scrutiny around its R&D disclosures. For investors following NasdaqGS:BIIB, the halt of BIIB122...